Pantarhei Bioscience BV (PRB) is a company in The Netherlands with an innovative concept of drug development in Woman’s Health. PRB's wholly owned subsidiary company – Pantarhei Oncology (PRO) (http://www.pantarheioncology.nl) develops innovative treatments for Endocrine Cancer. PRB and PRO have developed a product pipeline based on the proven ability to identify novel medical uses of existing molecules, drugs, hormones, biologicals and combinations thereof in these areas of medicine. The main areas of expertise of PRB are reproductive hormone related treatments such as contraception and menopausal hormone therapy (MHT). The main areas of expertise of PRO are and in oncology breast cancer, prostate cancer and ovarian cancer. The business concept of PRB and PRO is to develop the patented new treatment concepts up to proof-of-concept (PoC) in the human (phase II). Using existing molecules often provides first evidence of safety. The business model is based on solid patent protection, internal project management and external research and development activities. Intellectual property (IP) and data supporting the new treatment concepts are licensed out for completion of clinical development (phase III), regulatory approval and sales and marketing by a licensee/partner.